Summary of the agenda for the PBAC July 2018 meeting

Summary of the agenda for the PBAC July 2018 meeting

The PBAC will consider 57 submissions (30 major & 27 minor) at its next scheduled meeting in July (Table 1).

Table 1. Submissions by technology type

Technology category	Number	Percentage
PBS medicine or vaccine	54	95
PBS medicinal preparation*	1	2
NIP vaccine	2	3
LSDP medicine**	0	0

PBS = Pharmaceutical Benefits Scheme; NIP = National Immunisation Program; LSDP = Life Saving Drugs Program. * Nutritional supplements; ** Section 100 or LSDP

The Committee will also consider six reports from the Drug Utilisation Subcommittee (DUSC) for medicines for:

·      Age-related macular degeneration & macular oedema (3 medicines)

·      Malignant melanoma (7 medicines)

·      Attention deficit-hyperactivity disorder (5 medicines)

·      Muscle spasticity/blepharospasm (3 medicines)

·      Gastro-oesophageal reflux disease (5 medicines)

·      Fungal infection (1 medicine)

13 (23%) of the 57 submissions are for a new medicine (Table 2).

Table 2. Submissions by listing type

Listing type	Number	Percentage
New medicine	13	23
New vaccine	0	0
New gene therapy	0	0
New biosimilar medicine	5	9
New indication	19	33
New combination product	3	6
Restriction change	5	9
New strength	3	5
New formulation	9	16
Review	0	0

17 (30%) of the 57 submissions are resubmissions; most are for a new medicine or a new indication (Table 3).

Table 3. Resubmissions by listing type

Listing type	Number	Percentage
New medicine	7	41
New indication	7	41
New combination product	2	12
New formulation	1	6

Just under a quarter of all submissions are for oncology medicines (Table 4).

Table 4. Submissions by therapeutic area

Therapeutic area	Number*	Percentage
Cardiovascular disease	1	2
Dermatology	0	0
Endocrinology	4	7
Gastroenterology	3	5
Genetic disease	2	3
Haematology	7	12
Hepatology	0	0
Immunology	12	21
Infectious disease	4	7
Musculoskeletal	1	2
Nephrology	1	2
Neurology	1	2
Nutrition	1	2
Obstetrics/Gynaecology	0	0
Oncology	13	23
Ophthalmology	1	2
Otolaryngology	0	0
Paediatrics	5	9
Psychiatry/Psychology	1	2
Respiratory disease	0	0
Rheumatology	0	0
Sleep	0	0
Urology	0	0

MSD is the leading applicant (Table 5).

Table 5. Submissions by applicant

Sponsor	Number of submissions	Number of major submissions
MSD	8	6
Amgen	4	3
Pfizer	4	1
BMS	3	3
Novartis	3	1
Roche	3	1